辅助化疗与切除胆道癌的观察相比:第三阶段随机对照试验的生存元分析
1Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye; Ankara University Cancer Research Institute, Ankara, Türkiye.
European journal of cancer (Oxford, England : 1990)
|March 18, 2025
概括
基于5-FU的辅助化疗改善了胆道癌的无复发性和整体存活率. 基于吉姆西塔的化疗没有显示任何益处,突出显示需要更有效的长期辅助治疗.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 胆道癌 (BTC) 的复发率很高,手术后的生存率很差.
- 有限的随机对照试验 (RCT) 存在于BTCs的辅助化疗中.
- 目前的辅助治疗提供了有限的长期生存益处.
研究的目的:
- 在切除的BTC中评估辅助化疗的疗效.
- 为了比较基于5-FU和基于gemcitabine的化疗方案.
- 分析短期 (2年) 和长期生存结果.
主要方法:
- 对4项涉及1308名患者的第三阶段RCT的元分析.
- 辅助化疗与观察的比较.
- 主要终点:无复发生存率 (RFS) 和整体生存率 (OS).
- 从卡普兰-梅尔曲线对比例危险结果和患者数据的分析.
主要成果:
- 基于5-FU的化疗显著改善了RFS (HR:0.80) 和OS (HR:0.78).
- 基于凝胺的化疗对RFS (HR:0.90) 或OS (HR:1.03) 没有显著的益处.
- 基于5-FU的化疗的益处在前2年更为明显 (RFS HR:0.67,OS HR:0.61).
- 基于凝胺的化疗没有显示短期RFS益处和潜在的有害OS影响 (HR:1.22).
结论:
- 基于5-FU的单疗法被证实是切除BTC的有效辅助治疗.
- 基于5-FU的化疗的显著短期益处强调了需要改进的长期辅助策略的需要.
- 对OS和RFS的两年比例危险被建议作为未来试验的次要终点.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
01:20Comparing the Survival Analysis of Two or More Groups
110
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
110